Achaogen, Inc.
Achaogen, Inc. (AKAO): 3 pipeline candidates · ~4 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.8 months
D/E -14.09 · 0% dilution
Lead: Approved
3 candidates
N/A
N/A
A transparent, data-derived signal for Achaogen, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$56.5M
Quarterly Burn
$45.9M
Runway
3.8 mo
Revenue
$2.0M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| c-scape | Phase 1 |
| plazomicin | BLA Filed |
| zemdri | Approved |
Frequently asked questions
How many drug candidates are in Achaogen, Inc.'s pipeline?
Achaogen, Inc. (AKAO) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Achaogen, Inc.'s lead drug candidate?
Achaogen, Inc.'s most advanced tracked candidate is c-scape (Phase 1) for serious bacterial infections due to expanded spectrum beta-lactamases (ESBL) producing Enterobacteriaceae.
What is Achaogen, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Achaogen, Inc. has approximately 3.8 months of cash runway.
Get the full picture on Achaogen, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.